Products
Tixentamig Biosimilar Bispecific Antibody (CD3 × Claudin-18) for Research
Cat No.: GMP-Bios-INN-1418
Anti-CD3E therapeutic antibody (Pre-made Tixentamig biosimilar,Bispecific Mixed Domains (H-gamma1_L-kappa)_scFvhh-G1(h-CH2-CH3)) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Tixentamig (development code AZD5863) is a humanized bispecific antibody targeting CD3 and claudin 18.2 (CLDN18). It is developed by AstraZeneca for Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma et al. in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1418-1mg | 1mg | |
| GMP-Bios-INN-1418-10mg | 10mg | |
| GMP-Bios-INN-1418-100mg | 100mg | |
| GMP-Bios-INN-1418-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Tixentamig biosimilar, Bispecific Mixed Domains (H-gamma1_L-kappa)_scFvhh-G1(h-CH2-CH3), Anti-CD3E;CLDN18 Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
| INN Name | Tixentamig |
| Target | CD3E;CLDN18 |
| Format | Bispecific Mixed Domains (H-gamma1_L-kappa)_scFvhh-G1(h-CH2-CH3) |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;na |
| VD LC | Lambda;na |
| Highest_Clin_Trial (Jan '20) | TBC |
| Est. Status | TBC |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2025 |
| Year Recommended | na |
| Companies | TBC |
| Conditions Approved | TBC |
| Conditions Active | TBC |
| Conditions Discontinued | TBC |
| Production | na |
| Development Tech | TBC |
